Focus: Compass Pathways is a UK-based biotechnology company focused on psilocybin-assisted therapy for psychiatric disorders, operating in the emerging psychedelic medicine space. The company is advancing a clinical-stage pipeline targeting treatment-resistant depression, major depressive disorder, and other psychiatric indications.
Profile data last refreshed 15h ago · AI intelligence enriched 1mo ago
Cooling — net -12 jobs in 30d
9 added, 21 removed. Slower than typical.
Best suited for risk-tolerant professionals seeking ground-floor exposure to a novel therapeutic modality with clear near-term clinical catalysts but substantial regulatory and market adoption uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Compass Pathways
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Compass Pathways's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics - Fierce Biotech
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics Fierce Biotech
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies - Proactive Investors
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies Proactive Investors
Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data? - finance.yahoo.com
Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data? finance.yahoo.com
Psychedelic: Compass Pathways reports six-month data for psilocybin drug - TipRanks
Psychedelic: Compass Pathways reports six-month data for psilocybin drug TipRanks
Why This Psychedelics Stock Reversed Its Bearish Fortunes - Investor's Business Daily
Why This Psychedelics Stock Reversed Its Bearish Fortunes Investor's Business Daily
Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing - Endpoints News
Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo